You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Health state probabilities used in the model, based on the TRIPLE study

From: Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan

Health state outcome by phase PALO regimen N = 414 (%) GRA regimen N = 413 (%)
Acute Phase (day 1) Delayed Phase (days 2–5)
Complete protection Complete protection 58.7 50.4
Complete response at best 1.8 2.9
Incomplete response 29.6 36.9
Complete response at best Complete protection 1.1 1.0
Complete response at best 0.0 0.1
Incomplete response 0.6 0.7
Incomplete response Complete protection 5.3 4.6
Complete response at best 0.2 0.3
Incomplete response 2.7 3.4